Compare · DVA vs MRAI
DVA vs MRAI
Side-by-side comparison of DaVita Inc. (DVA) and Marpai Inc. (MRAI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DVA and MRAI operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- DVA is the larger of the two at $12.33B, about 283.2x MRAI ($43.5M).
- DVA has been more active in the news (12 items in the past 4 weeks vs 9 for MRAI).
- DVA has more recent analyst coverage (13 ratings vs 0 for MRAI).
- Company
- DaVita Inc.
- Marpai Inc.
- Price
- $192.05-0.05%
- $0.92-55.67%
- Market cap
- $12.33B
- $43.5M
- 1M return
- -2.08%
- -
- 1Y return
- +39.45%
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 12
- 9
- Recent ratings
- 13
- 0
DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Marpai Inc.
Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market. It also offers ancillary services, such as care management, case management, actuarial services, health savings account administration, and cost containment services. The company was incorporated in 2021 and is based in Tampa, Florida.
Latest DVA
- DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Yale Phyllis R gifted 5,038 shares, decreasing direct ownership by 35% to 9,525 units (SEC Form 4)
- Director Pullin Dennis W was granted 250 shares, increasing direct ownership by 10% to 2,671 units (SEC Form 4)
- Director Schoppert Wendy Lee was granted 250 shares (SEC Form 4)
- Director Moore Gregory J. was granted 250 shares, increasing direct ownership by 3% to 7,813 units (SEC Form 4)
- Director Arway Pamela M was granted 250 shares, increasing direct ownership by 0.94% to 26,945 units (SEC Form 4)
- Director Yale Phyllis R was granted 250 shares, increasing direct ownership by 2% to 14,563 units (SEC Form 4)
- Director Hollar Jason M. was granted 250 shares, increasing direct ownership by 4% to 6,605 units (SEC Form 4)
- Director Desoer Barbara J was granted 250 shares (SEC Form 4)
- Director Schechter Adam H was granted 250 shares, increasing direct ownership by 5% to 5,692 units (SEC Form 4)
Latest MRAI
- Director Eitan Yaron returned 50,000 shares to the company and was granted 175,000 shares, decreasing direct ownership by 4% to 1,224,073 units (SEC Form 4)
- Chief Financial Officer Johnson Steve Andrew was granted 125,000 shares and bought $682 worth of shares (1,100 units at $0.62), increasing direct ownership by 14% to 1,024,192 units (SEC Form 4)
- Director Shiv Sagiv returned 50,000 shares to the company and was granted 125,000 shares, decreasing direct ownership by 8% to 613,667 units (SEC Form 4)
- Director Pons Robert M returned 50,000 shares to the company and was granted 100,000 shares, decreasing direct ownership by 9% to 484,200 units (SEC Form 4)
- Director Calabrese Jennifer Rosario returned 50,000 shares to the company and was granted 100,000 shares, decreasing direct ownership by 18% to 225,000 units (SEC Form 4)
- Chief Executive Officer Lamendola Damien was granted 300,000 shares, increasing direct ownership by 22% to 1,650,000 units (SEC Form 4)
- Director Diclaudio Colleen was granted 125,000 shares, increasing direct ownership by 88% to 267,500 units (SEC Form 4)
- Marpai Inc. Announces Unprecedented Growth with 192,000 New Estimated Member Lives Across TPA and MarpaiRx PBM Platforms; Expects to Achieve Positive Cash Flow and EBITDA Beginning August 2026
- Director Eitan Yaron bought $2,700 worth of shares (10,000 units at $0.27), increasing direct ownership by 0.92% to 1,099,073 units (SEC Form 4)
- SEC Form 10-Q filed by Marpai Inc.